Janne T. Backman, MD, PhD is Professor in Clinical Pharmacology and Individual Medicine at Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital in Finland. Apart from teaching medical students, he is responsible for the medical specialist training program in clinical pharmacology in Helsinki. In addition to his multiple national roles, he serves as the Chairperson of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Ha has recently led the organization of the 17th EACPT Congress, which took place in Helsinki in 2025. Dr. Backman’s research primarily focuses on drug–drug interactions and other factors contributing to individual variability in pharmacokinetics and drug safety. He has carried out tens of academic clinical trials and authored over 200 original articles in international peer-reviewed journals. His H-index is >70 (Scopus). He is a member of the Finnish Academy of Science and Letters.

Shuang Lu is a second-year PhD student in Clinical Pharmacology at the School of Pharmaceutical Sciences, Fudan University, China. Her research centers on population pharmacokinetics (PPK) and pharmacokinetic–pharmacodynamic (PK/PD) modeling, with a particular passion for advancing scientific understanding in the medicinal cannabis field. She is actively involved in developing robust PopPK models, integrating real-world PK data, and exploring translational applications that support evidence-based clinical use of cannabinoids. Her work reflects a deep commitment to combining quantitative pharmacology with meaningful clinical impact.

Dr. Nan-Lin Wu is the Chief of Department of Dermatology at MacKay Memorial Hospital, Taipei, Taiwan, and a Professor at the Department of Medicine and Institute of Biomedical Sciences, MacKay Medical University, Taiwan. He earned his MD and PhD from National Taiwan University. Clinically, he specializes in psoriasis, atopic dermatitis, and other immunological skin diseases, having served as a principal investigator for numerous clinical trials in these fields. His research interests encompass inflammatory diseases, keratinocyte biology, natural/herbal compounds, photobiology, and clinical pharmacology.

Dominika is a PhD candidate at the Monash Institute of Pharmaceutical Sciences. Her PhD research focuses on the development of novel mechanisms-based mathematical models that can describe and predict full time-courses of bacterial growth and resistance emergence to combat multidrug-resistant bacteria that can cause life-threatening infections. She’s passionate about investigating ways to treat resistant bacterial “superbugs” by optimising dosing regimens of currently available antibiotics in the fight against antimicrobial resistance."

Amedeo De Nicolò, PhD, is an Associate Professor in Pharmacology at the University of Turin (UniTo) specializing in pharmacokinetics and PK/PD modeling. He holds a PhD in Medicine and Experimental Therapy, focusing his research on drug metabolism, particularly for HIV and infectious diseases, using advanced HPLC-MS/MS techniques.

Yanbiao Liu was previously trained in general and oncologic surgery in China and is now pursuing a PhD in pharmacology and biomedicine at Auckland University of Technology, New Zealand. His research focuses on the functional role of sperm-associated antigen 5 (SPAG5) in breast cancer and its influence on cellular responses to chemotherapeutic and targeted agents.